A detailed history of Charles Schwab Investment Management Inc transactions in Edgewise Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 497,162 shares of EWTX stock, worth $8.95 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
497,162
Previous 331,059 50.17%
Holding current value
$8.95 Million
Previous $3.62 Million 150.43%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 08, 2024

BUY
$9.25 - $19.97 $1.54 Million - $3.32 Million
166,103 Added 50.17%
497,162 $9.07 Million
Q4 2023

Feb 06, 2024

BUY
$5.51 - $12.1 $1,102 - $2,420
200 Added 0.06%
331,059 $3.62 Million
Q3 2023

Nov 08, 2023

BUY
$5.73 - $7.69 $114,525 - $153,700
19,987 Added 6.43%
330,859 $1.9 Million
Q2 2023

Aug 09, 2023

BUY
$5.71 - $10.29 $94,563 - $170,412
16,561 Added 5.63%
310,872 $2.41 Million
Q1 2023

May 11, 2023

SELL
$6.66 - $11.33 $17,076 - $29,050
-2,564 Reduced 0.86%
294,311 $1.96 Million
Q4 2022

Feb 13, 2023

BUY
$7.58 - $11.08 $713,293 - $1.04 Million
94,102 Added 46.41%
296,875 $2.65 Million
Q3 2022

Nov 14, 2022

BUY
$8.08 - $13.58 $707,169 - $1.19 Million
87,521 Added 75.94%
202,773 $2 Million
Q2 2022

Aug 15, 2022

SELL
$5.67 - $9.87 $170,400 - $296,623
-30,053 Reduced 20.68%
115,252 $918,000
Q1 2022

May 13, 2022

BUY
$9.1 - $18.97 $44,681 - $93,142
4,910 Added 3.5%
145,305 $1.41 Million
Q4 2021

Feb 11, 2022

BUY
$14.41 - $22.41 $811,066 - $1.26 Million
56,285 Added 66.92%
140,395 $2.15 Million
Q3 2021

Nov 16, 2021

BUY
$14.11 - $24.1 $42,837 - $73,167
3,036 Added 3.74%
84,110 $1.4 Million
Q2 2021

Aug 16, 2021

BUY
$21.33 - $30.25 $1.73 Million - $2.45 Million
81,074 New
81,074 $1.73 Million

Others Institutions Holding EWTX

About Edgewise Therapeutics, Inc.


  • Ticker EWTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 63,171,700
  • Market Cap $1.14B
  • Description
  • Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has c...
More about EWTX
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.